CRISPR Therapeutics AG Profit Margin

CRISPR Therapeutics AG (CRSP) currently reports a profit margin of -1812.07% as of September 2026. That compares with -1327.58% in the prior-year period — down 36.5% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore CRISPR Therapeutics AG's profit margin history and peer comparisons.

CRISPR Therapeutics AG's profit margin decreased from -1327.58% to -1812.07% — a 36.5% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CRISPR Therapeutics AG's profit margin of -1812.07% is lower than the Healthcare sector average of 9.48%. That is roughly 19212.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but CRISPR Therapeutics AG's current -1812.07% should be judged against Healthcare norms (sector average: 9.48%) and against CRSP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1812.07%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for CRISPR Therapeutics AG, and consider following CRSP for alerts when major investors trade the stock.